author-photo

Céline Ferlay

University of Lyon

39

Papers

1005

Citations

Citation Trend

Filter By

Papers (25) Sort By

Journal Conference Others

REGOSTA: A randomized, placebo-controlled, double-blinded, multicenter study evaluating the efficacy and safety of regorafenib (REGO) as maintenance therapy after first-line treatment in patients (pts) with osteosarcoma (OS) and non-osteosarcomas (non-OS) of bone (non-Ewing, non-chondrosarcomas and non-chordomas).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial

2020 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (17)
Exclusive Hyper-fractionated Radiotherapy and reduced boost volume for standard-risk medulloblastoma: pooled analysis of the two French multicentric studies MSFOP98 and MSFOP 2007 and correlation with molecular subgroups

2020 International Journal of Radiation Oncology Biology Physics
Show All
- Source
- Cite
- Save
Citations (7)
Medulloblastoma Molecular Subgroup and Hyperfractionated Radiation Therapy Alone for Standard Risk Medulloblastoma : Results of the Pool Data of MSFOP 1998 and 2007 Studies

2019 International Journal of Radiation Oncology Biology Physics
Show All
- Source
- Cite
- Save
Citations (0)
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial

2019 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (69)
Pazopanib (P) and bevacizumab (B) in patients with metastatic renal cell carcinoma (mRCC) or other advanced refractory tumors: Phase I combination study final analysis.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Updated results on long-term overall survival (OS) of the French randomized phase II trial TORAVA in metastatic renal cell carcinoma (mRCC) patients.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase I study of pazopanib (P) combined with bevacizumab (B) in patients with metastatic renal cell carcinoma (mRCC) or other advanced refractory tumors.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial

2016 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (245)